341001-38-5 Usage
General Description
Methanone, [4-(2-chloro-4-nitrophenyl)-1-piperazinyl](5-methyl-3-phenyl-4-isoxazolyl)-, also known as isoxoprine, is a chemical compound with a complex molecular structure. It is a piperazine derivative that has been studied for its potential pharmacological properties, particularly in the field of neuroscience and cardiovascular medicine. Isoxoprine has been investigated for its vasodilatory and antiplatelet effects, and it has been used in the treatment of peripheral vascular diseases. Additionally, it has also been studied for its potential in improving blood flow in the brain and for its anti-inflammatory properties. Despite its potential therapeutic benefits, further research is needed to fully understand the pharmacological effects and safety profile of isoxoprine.
Check Digit Verification of cas no
The CAS Registry Mumber 341001-38-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,1,0,0 and 1 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 341001-38:
(8*3)+(7*4)+(6*1)+(5*0)+(4*0)+(3*1)+(2*3)+(1*8)=75
75 % 10 = 5
So 341001-38-5 is a valid CAS Registry Number.
InChI:InChI=1/C21H19ClN4O4/c1-14-19(20(23-30-14)15-5-3-2-4-6-15)21(27)25-11-9-24(10-12-25)18-8-7-16(26(28)29)13-17(18)22/h2-8,13H,9-12H2,1H3
341001-38-5Relevant articles and documents
METHANETHIONE COMPOUNDS HAVING ANTIVIRAL ACTIVITY
-
Page/Page column 23, (2013/12/03)
A compound of formula (I), The compound is useful as an antiviral agent, in particular for the treatment of influenza. A method for preparing the compound of formula (I) and a composition comprising the compound of formula (I).
ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF
-
, (2011/09/20)
Compounds which exhibit antiviral activity, particularly against influenza virus, and methods of making and using thereof are described herein. In one embodiment, the compounds are heterocyclic amides containing piperazine and isozazole rings and optionally substituted with one or more substituents. The compounds can be formulated with one or more pharmaceutically acceptable excipients to form compositions suitable for enteral or parenteral administration. The compounds are preferably used to treat or prevent Influenza A infections, such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7.